Miltefosine

Miltefosine (INN, trade names Impavido and Miltex) is a broad-spectrum phospholipid antimicrobial drug. Chemically, it is a derivative of lysophospatidylcholine. It was developed in the late 1980s as an experimental cancer treatment by German scientists Hansjörg Eibl and Clemens Unger. Simultaneously, but independently, it was found that the drug could kill Leishmania parasites, and since the mid-1990s, successful clinical trials were conducted. The drug became the first (and still the only prescribed) oral drug in the treatment of leishmaniasis. It is now known to be a broad-spectrum antimicrobial drug, active against pathogenic bacteria and fungi, as well as human trematode Schistosoma mansoni and its vector host, the snail Biomphalaria alexandrina. It can be administered orally and topically.